Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 1/20 | 0.62 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.62 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 16/20 | 0.52 |
| ▸ | AGXT | P21549 | 7/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | MGMT | P16455 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10157517 | 0.83 | LOXL2 (0.61) | LOXLOXL3LOXL2RECQLIDO1 | |
| SCHEMBL1145877 | 0.80 | LOX (0.57) | LOXLOXL3LOXL2RECQLGRM5 | |
| SCHEMBL1145875 | 0.80 | LOX (0.57) | LOXLOXL3LOXL2RECQLIDO1 | |
| SCHEMBL904475 | 0.77 | — | — | |
| SCHEMBL28775209 | 0.77 | RECQL (0.53) | LOXLOXL3LOXL2RECQLGRM5 | |
| SCHEMBL23860789 | 0.76 | TSHR (0.54) | LOXLOXL3LOXL2RECQLGRM5 | |
| SCHEMBL3370181 | 0.76 | GRM5 (0.52) | LOXLOXL3LOXL2RECQLGRM5 | |
| SCHEMBL29411261 | 0.75 | RECQL (0.47) | LOXLOXL3LOXL2RECQLGRM5 | |
| SCHEMBL1766223 | 0.75 | RECQL (0.47) | LOXLOXL3LOXL2RECQLGRM5 | |
| Hydrochloric Acid SCHEMBL14759174 | 0.75 | LOXL2 (0.96) | LOXLOXL3LOXL2RECQLGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| EP-2040698-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | LOX 570/4885LOXL3 254/4885LOXL2 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.